All In Biotech

Drug Trial Radar · NCT03177902

Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer

A Prospective Study to Assess Both Thyroid Abnormity Incidence In Chinese Women With Newly Diagnosed Breast Cancer and Thyroid Toxicity of Breast Cancer Patients Undergoing Chemotherapy

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jun 4, 2017

Primary completion

Apr 2027

Study completion Jun 2027

Sponsor

Lead sponsor
The First Affiliated Hospital of Bengbu Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 6, 2017

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 85 years

Summary

As written by the sponsor on the registry.

Breast cancer is one of the most common cancers in China. Even though advances in the field of breast cancer therapeutics, chemotherapy remains the mainstay therapeutic modality. The cytotoxic therapies are generally associated with some immediate or otherwise delayed side effects, such as adverse effects on gastrointestinal, hepatic, renal and hematological systems. The effect of chemotherapy on endocrine system, however, is comparatively less envisaged. Several epidemiological studies show a positive association between plasma thyroid hormones levels and breast cancer risk. Thyroid dysfunction is emerging as a variably common endocrine toxicity of several anticancer drugs. Due to the scarcity of data on the functioning of thyroid gland during chemotherapy in a large scale group, the present study was aimed to investigate the incidence of thyroid abnormity in Chinese women with newly diagnosed breast cancer, and also the effects of chemotherapy on thyroid gland functions or structure in these breast cancer patients undergoing at least four cycles of chemotherapy.

Conditions

  • Breast Cancer Female
  • Thyroid Gland

Interventions

  • ChemotherapyDrug

    Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants newly diagnosed with breast cancerTime frame: 1 week around the indicated detection point

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.